This hypothesis is consistent with the recent findings that GLP-1 agents have been shown to decrease the incidence of cardiovascular disease and stroke in patients with obesity and without diabetes (62). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.